ArticleDrug design, development and therapy2025
Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fluorescent properties of FDA-approved anti-leukemia drugs.Biomedical optics express · 2026Article
- Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Currently reported methods for determining plasma concentration of mitoxantrone primarily measure total drug concentration. However, methodologies for quantifying liposomal mitoxantrone, particularly the free drug fraction, are lacking. Since the free drug represents the pharmacologically active moiety responsible for therapeutic effects, this study aimed to establish a detection method for total and free concentration of liposomal mitoxantrone in human plasma, while also exploring the temporal changes in drug concentration throughout the dosing cycle for liposomal mitoxantrone. Patients and Methods: For total mitoxantrone, the mobile phase consisted of 10 mmol/L KH Results: The linear calibration range of total and free mitoxantrone were 0.1-5 µg/mL and 5-500 ng/mL (r Conclusion: In this study, we established UPLC and UPLC-MS/MS methods for determining the total and free concentrations of liposomal mitoxantrone which were highly efficient, accurate, specific and suitable for clinical application and investigating the pharmacokinetics. Correlation analysis revealed that gender might be an important factor influencing the concentration of liposomal mitoxantrone in patients with relapsed or refractory peripheral T-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.